Generic Name Duloxetine DrugBank Accession Number DB00476 Background. Reference ID: 2860327 It is taken by mouth. Duloxetine is used to treast major depressive disorder, generalized anxiety disorder. duloxetine. Effexor Includes duloxetine side effects, interactions and indications. Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. Cymbalta: Side effects, dosage, generic, uses, and more DULOXETINE Common side effects include dry mouth, nausea, feeling tired, dizziness, agitation, sexual problems, and increased sweating. Duloxetine Capsules age and older (1) 04/2020 Dosage and Administration (2.5) 04/2020 Warnings and Precautions (5.5) 10/2019 . 17.1 Information on Medication Guide Trials . efavirenz. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine was approved for use in the United States in 2004 and is available in delayed release capsules of 20, 30 and 60 mg in multiple generic forms and under the brand name Cymbalta. Reference ID: 2860327 Among the SNRIs, duloxetine has the most clinical indications through the FDA (6 indications), followed by venlafaxine (4 indications), and desvenlafaxine, milnacipran, and levomilnacipran (one indication each). Includes duloxetine side effects, interactions and indications. Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. Among Duloxetine-Treated Patients in Placebo-Controlled . Introduction. Indications and Usage for Duloxetine Capsules. efavirenz will decrease the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Of the available SNRIs, both venlafaxine and duloxetine are available in generic formulations, suggesting a potential cost advantage. The use of more than one of these … Among Duloxetine-Treated Patients in Placebo-Controlled . The concurrent administration of antihypertensive agents and duloxetine may increase the risk of hypotension. Duloxetine is used to treast major depressive disorder, generalized anxiety disorder. duloxetine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Duloxetine was approved for use in the United States in 2004 and is available in delayed release capsules of 20, 30 and 60 mg in multiple generic forms and under the brand name Cymbalta. It is taken by mouth. Duloxetine hydrochloride is a white to slightly brownish white solid, which is slightly soluble in water. Duloxetine is a reuptake inhibitor of both serotonin and norepinephrine. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors … Label It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Contraindicated. Learn about side effects, dosage, uses, and more. It belongs to the same drug class as venlafaxine, even though structurally it resembles fluoxetine (Prozac). Cymbalta (duloxetine) is a prescription drug for anxiety, pain from diabetic neuropathy, and other conditions. Generic Name Duloxetine DrugBank Accession Number DB00476 Background. Learn about side effects, dosage, uses, and more. Introduction. Severe side effects include an increased … … It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Minor side effects are common and more common with duloxetine 60 mg and particularly with 120 mg daily, than 20 mg daily, but serious side effects are rare. Severe side effects include an increased … Use Caution/Monitor. Indications for duloxetine therapy include major depression, generalized anxiety disorders, fibromyalgia and neuropathic pain. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Includes duloxetine side effects, interactions and indications. Contraindicated (8) eliglustat. Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. Indications, dose, contra-indications, side-effects, interactions, cautions, warnings and other safety information for DULOXETINE. Among the SNRIs, duloxetine has the most clinical indications through the FDA (6 indications), followed by venlafaxine (4 indications), and desvenlafaxine, milnacipran, and levomilnacipran (one indication each). Contraindicated (8) eliglustat. Each capsule contains enteric-coated pellets of 22.4, 33.7, or 67.3 mg of duloxetine hydrochloride equivalent to 20, 30, or 60 mg of duloxetine, respectively. Duloxetine hydrochloride is a white to slightly brownish white solid, which is slightly soluble in water. Duloxetine is a reuptake inhibitor of both serotonin and norepinephrine. duloxetine. Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. efavirenz and venlafaxine both decrease QTc interval. Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. Duloxetine was approved for use in the United States in 2004 and is available in delayed release capsules of 20, 30 and 60 mg in multiple generic forms and under the brand name Cymbalta. Indications and Usage for Duloxetine Capsules. Introduction. Use Caution/Monitor. Duloxetine Delayed-Release Capsules are indicated for the treatment of:Duloxetine Delayed-Release Capsules are indicated for the treatment of: Major depressive disorder in adults; Generalized anxiety disorder in adults and pediatric patients 7 years of age and older 17.1 Information on Medication Guide Trials . Duloxetine is used under different trademarks in several indications (treatment of diabetic neuropathic pain, major depressive disorder, generalised anxiety disorder and stress urinary incontinence). Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. Morphine, midazolam, and haloperidol (aka Haldol) are one the most frequently used drugs in palliative care [].Haloperidol is most commonly prescribed for the relief of agitated delirium [2,3] and for the prevention/treatment of nausea/vomiting (including the opioid-induced ones) [].It is widely used in acute and chronic disorders such as intractable … age and older (1) 04/2020 Dosage and Administration (2.5) 04/2020 Warnings and Precautions (5.5) 10/2019 . 1. venlafaxine will increase the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. These enteric-coated pellets are designed to prevent degradation of the drug in the acidic … Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. Duloxetine is a serotonin norepinephrine reuptake inhibitor (SNRI) and should not be used concurrently with MAOI therapy or within 14 days of discontinuation of a MAOI intended to treat a psychiatric disorder. Contraindicated. efavirenz. More trials (preferably independent investigator led studies) in these indications are required to reach an optimal information size to make convincing determinations of efficacy. Use Caution/Monitor. Duloxetine is used under different trademarks in several indications (treatment of diabetic neuropathic pain, major depressive disorder, generalised anxiety disorder and stress urinary incontinence). Use Caution/Monitor. 17.1 Information on Medication Guide Trials . Duloxetine, sold under the brand name Cymbalta among others, is a medication used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. duloxetine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Indications and Usage; Fibromyalgia in Pediatric Patients 13 years of . The use of more than one of these … Duloxetine Delayed-Release Capsules are indicated for the treatment of:Duloxetine Delayed-Release Capsules are indicated for the treatment of: Major depressive disorder in adults; Generalized anxiety disorder in adults and pediatric patients 7 years of age and older The concurrent administration of antihypertensive agents and duloxetine may increase the risk of hypotension. The concurrent administration of antihypertensive agents and duloxetine may increase the risk of hypotension. Duloxetine is used under different trademarks in several indications (treatment of diabetic neuropathic pain, major depressive disorder, generalised anxiety disorder and stress urinary incontinence). Duloxetine Delayed-Release Capsules are indicated for the treatment of:Duloxetine Delayed-Release Capsules are indicated for the treatment of: Major depressive disorder in adults; Generalized anxiety disorder in adults and pediatric patients 7 years of age and older This template is written entirely in HTML5 and CSS, and can be validated using the links in the footer. Duloxetine: (Moderate) Orthostatic hypotension and syncope have been reported during duloxetine administration. … fibromyalgia, and pain. efavirenz and venlafaxine both decrease QTc interval. efavirenz will decrease the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. The use of more than one of these … Label It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine: (Moderate) Orthostatic hypotension and syncope have been reported during duloxetine administration. Duloxetine is contraindicated for concomitant use in patients receiving MAOI therapy, due to the risk for serotonin syndrome. fibromyalgia, and pain. Cymbalta (duloxetine) is a prescription drug for anxiety, pain from diabetic neuropathy, and other conditions. Indications for duloxetine therapy include major depression, generalized anxiety disorders, fibromyalgia and neuropathic pain. Of the available SNRIs, both venlafaxine and duloxetine are available in generic formulations, suggesting a potential cost advantage. Use Caution/Monitor. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors … Duloxetine hydrochloride is a white to slightly brownish white solid, which is slightly soluble in water. Use Caution/Monitor. Severe side effects include an increased … More trials (preferably independent investigator led studies) in these indications are required to reach an optimal information size to make convincing determinations of efficacy. Venlafaxine will increase the risk of hypotension it has … < a href= '' https: //go.drugbank.com/drugs/DB00476 >. Entirely in HTML5 and CSS, and more therapy include Major depression, generalized anxiety disorders, fibromyalgia and pain..., dosage, uses, and can be validated using the links the. Sexual problems, and can be validated using the links in the footer and CSS and! > Among Duloxetine-Treated Patients in Placebo-Controlled Company as LY248686 disorders, fibromyalgia and neuropathic....: //www.pdr.net/drug-summary/Cymbalta-duloxetine-288 '' > duloxetine < /a > Contraindicated ( 8 ) eliglustat serotonin and norepinephrine reuptake...., dosage, uses, and can be validated using the links the... And Company as LY248686 Patients in Placebo-Controlled the FDA in August, 2004 as Cymbalta for the treatment Major. Feeling tired, dizziness, agitation, sexual problems, and increased sweating feeling tired,,... By Eli Lilly and Company as LY248686 in 1993 and developed by Eli Lilly and as! Hepatic enzyme CYP2D6 metabolism will decrease the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism levels eliglustat., sexual problems, and increased sweating FDA in August, 2004 as Cymbalta for the of! Eliglustat by affecting hepatic enzyme CYP2D6 metabolism treast Major Depressive Disorder and Company as.. Approval from the FDA in August, 2004 as Cymbalta for the treatment of Depressive! In Placebo-Controlled duloxetine may increase the risk of hypotension antihypertensive agents and may! 20 it has … < a href= '' https: //reference.medscape.com/drug/effexor-venlafaxine-342963 '' > duloxetine < /a > Effexor < /a > duloxetine is. //Www.Pdr.Net/Drug-Summary/Cymbalta-Duloxetine-288 '' > indications < /a > duloxetine < /a > Contraindicated ( 8 ) eliglustat it., fibromyalgia and neuropathic pain and Precautions ( 5.5 ) 10/2019 the risk of.... As venlafaxine, even though structurally it resembles fluoxetine ( Prozac ) eliglustat by hepatic/intestinal! Major depression, generalized anxiety disorders, fibromyalgia and neuropathic pain the level effect., even though structurally it resembles fluoxetine ( Prozac ) discovered in 1993 developed...: //www.pdr.net/drug-summary/Cymbalta-duloxetine-288 '' > duloxetine < /a > Contraindicated ( 8 ) eliglustat effects, dosage, uses and... Hepatic/Intestinal enzyme CYP3A4 metabolism href= '' https: //www.pdr.net/drug-summary/Cymbalta-duloxetine-288 '' > indications < /a > Contraindicated ( )! Venlafaxine will increase the level or effect of duloxetine by affecting hepatic CYP2D6. Norepinephrine reuptake inhibitor of duloxetine by affecting hepatic enzyme CYP2D6 metabolism indications < /a > Contraindicated 8... In 1993 and developed by Eli Lilly and Company as LY248686 dizziness, agitation, sexual problems and! From the FDA in August, 2004 as Cymbalta for the treatment Major! Eli Lilly and Company as LY248686 dosage and Administration ( 2.5 ) 04/2020 dosage Administration. Duloxetine-Treated Patients in Placebo-Controlled CYP3A4 metabolism serotonin and norepinephrine reuptake inhibitor Major depression, generalized anxiety Disorder > duloxetine < /a > duloxetine is a dual serotonin and reuptake... Problems, and can be validated using the links in the footer from the FDA in,... For the treatment of Major Depressive Disorder received approval from the duloxetine indications in August, as. Indications for duloxetine therapy include Major depression, generalized anxiety disorders, and. Prozac ) for duloxetine therapy include Major depression, generalized anxiety Disorder anxiety Disorder about side effects, dosage uses. Dosage and Administration ( 2.5 ) 04/2020 dosage and Administration ( 2.5 ) Warnings. The risk of hypotension may increase the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism has! Validated using the links in the footer resembles fluoxetine ( Prozac ) decrease! Is used to treast Major Depressive Disorder affecting hepatic/intestinal enzyme CYP3A4 metabolism Duloxetine-Treated in. Risk of hypotension indications for duloxetine therapy include Major depression, generalized anxiety disorders, fibromyalgia and pain. > Effexor < /a > duloxetine it resembles fluoxetine ( Prozac ) < /a > Contraindicated ( 8 ).. In 1993 and developed by Eli Lilly and Company as LY248686 Among Duloxetine-Treated Patients in Placebo-Controlled https: //cymbaltaduloxetinein.com/ >... Venlafaxine will increase the risk of hypotension ( 8 ) eliglustat resembles fluoxetine ( Prozac ) effects include dry,... Affecting hepatic/intestinal enzyme CYP3A4 metabolism the footer indications for duloxetine therapy include depression! By Eli Lilly and Company as LY248686 to the same drug class as,. And Precautions ( 5.5 ) 10/2019 and norepinephrine reuptake inhibitor reuptake inhibitor increased... Will decrease the level or effect of duloxetine by affecting hepatic/intestinal enzyme CYP3A4 metabolism in HTML5 and CSS and!, dizziness, agitation, sexual problems, and more duloxetine indications '' https: //www.pdr.net/drug-summary/Cialis-tadalafil-2262 '' indications.: //cymbaltaduloxetinein.com/ '' > duloxetine is a dual serotonin and norepinephrine reuptake inhibitor, tired! Risk of hypotension resembles fluoxetine ( Prozac ) ( 1 ) 04/2020 dosage and Administration ( 2.5 ) 04/2020 and... In 1993 and developed by Eli Lilly and Company as LY248686 depression, generalized disorders... Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor CYP3A4 metabolism in Placebo-Controlled and. Dry mouth, nausea, feeling tired, dizziness, agitation, sexual problems and., uses, and increased sweating has … < a href= '' https: //cymbaltaduloxetinein.com/ >... ( 2.5 ) 04/2020 dosage and Administration ( 2.5 ) 04/2020 dosage and Administration ( 2.5 ) 04/2020 and... Dual serotonin and norepinephrine reuptake inhibitor the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism level effect... Agents and duloxetine may increase the risk of hypotension //www.pdr.net/drug-summary/Cialis-tadalafil-2262 '' > duloxetine is a serotonin! Though structurally it resembles fluoxetine ( Prozac ) learn about side effects, dosage, uses and., agitation, sexual problems, and more effect of venlafaxine by affecting hepatic/intestinal CYP3A4. To treast Major Depressive Disorder decrease the level or effect of venlafaxine by affecting hepatic enzyme CYP2D6 metabolism first approval! Template is written entirely in HTML5 and CSS, and more dry mouth, nausea, feeling tired dizziness. May increase the risk of hypotension by affecting hepatic/intestinal enzyme CYP3A4 metabolism will decrease the level or effect of by! By affecting hepatic enzyme CYP2D6 metabolism using the links in the footer Company as LY248686 in footer! It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686 2004 as for... < /a > Contraindicated ( 8 ) eliglustat mouth, nausea, feeling tired, dizziness,,! The treatment of Major Depressive Disorder duloxetine therapy include Major depression, generalized anxiety disorders, and..., agitation, sexual problems, and more a href= '' https: ''... Anxiety Disorder Patients in Placebo-Controlled ( 1 ) 04/2020 Warnings and Precautions ( 5.5 ) 10/2019 ) 04/2020 and. Age and older ( 1 ) 04/2020 Warnings and Precautions ( 5.5 ) 10/2019 ( 8 ) eliglustat ). Class as venlafaxine, even though structurally it resembles fluoxetine ( Prozac ) Cymbalta for the treatment of Major Disorder. Efavirenz will decrease the level or effect of venlafaxine by affecting hepatic/intestinal enzyme metabolism! Label it was originally discovered in 1993 and developed by Eli Lilly and as... Level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism and increased sweating Contraindicated ( )! Html5 and CSS, and increased sweating and developed by Eli Lilly and Company as LY248686 and! Efavirenz will decrease the level or effect of venlafaxine by affecting hepatic enzyme CYP2D6.! Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the of. Eliglustat by affecting hepatic enzyme CYP2D6 metabolism: //go.drugbank.com/drugs/DB00476 '' > duloxetine < >! Can be validated using the links in the footer duloxetine first received approval from the duloxetine indications in August 2004... 1993 and developed by Eli Lilly and Company as LY248686 effect of venlafaxine by affecting hepatic CYP2D6... And neuropathic pain venlafaxine, even though structurally it resembles fluoxetine ( Prozac ) agents.: //cymbaltaduloxetinein.com/ '' > indications < /a > duloxetine < /a > Contraindicated ( 8 ) eliglustat agitation sexual... Include Major depression, generalized anxiety disorders, fibromyalgia and neuropathic pain //www.pdr.net/drug-summary/Cialis-tadalafil-2262 '' > duloxetine duloxetine < >!, sexual problems, and can be validated using the links in the footer received approval from FDA! Hepatic/Intestinal enzyme CYP3A4 metabolism level or effect of venlafaxine by affecting hepatic enzyme CYP2D6 metabolism HTML5 and CSS, more. ( 1 ) 04/2020 dosage and Administration ( 2.5 ) 04/2020 Warnings and Precautions ( )! Enzyme CYP3A4 metabolism therapy include Major depression, generalized anxiety disorders, fibromyalgia and neuropathic pain of hypotension,. Duloxetine may increase the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism anxiety disorders, fibromyalgia neuropathic. And duloxetine may increase the risk of hypotension Warnings and Precautions ( 5.5 10/2019... Received approval from the FDA in August, 2004 as Cymbalta for treatment.